Pharmaceutical company Takeda JP:4502 announced Wednesday that the U.S. Food and Drug Administration has approved Fluzakura for the treatment of certain colorectal cancer patients.
Fluzacra (fruquintinib), an oral targeted therapy, has been approved for adults with metastatic colorectal cancer who have received certain prior treatments.
of…